Cardinal Health (CAH) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

—

Estimate

$2.42

Surprise

—

Score today

5.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

• TD Cowen Maintains Buy on Cardinal Health, Raises Price Target to $280 — benzinga, 2026-08-13
• JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $260 — benzinga, 2026-08-13
• Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $275 — benzinga, 2026-08-13

TrendMatrix currently rates CAH Sell at 5.8/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$229.51

Price target

$243.84

Stop

$217.39

Upside to target

+6.2%

Reward-to-risk

1.1:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Distribution

Market cap

$53.38B

P/E (fwd)

16.3

P/E (ttm)

31.7

52-week range

$145.87–$258.30

Off 52-week high

11.1%

RSI (14)

42

Volume vs avg

0.69×

Score today

5.8/10